Sector News

Bayer HealthCare's faltering even before Monsanto enters the fold

March 1, 2018
Life sciences

Industry watchers were worried about Bayer neglecting its healthcare division after the company chased down a megamerger with agrochemical giant Monsanto. But that deal hasn’t even closed yet, and healthcare sales are already showing cause for concern.

Wednesday, the German drugmaker unveiled fourth-quarter pharma sales of €4.21 billion, 4% below consensus estimates. Only one of Bayer’s five key growth products—a group consisting of eye drug Eylea, anticoagulant Xarelto, pulmonary arterial hypertension treatment Adempas and cancer therapies Stivarga and Xofigo—beat analyst estimates for the quarter, and that was Eylea, which came out 5.2% ahead.

Xofigo missed its €106 million target with just €90 million in sales, while Stivarga managed just €77 million. Another key miss came from hemophilia treatment Kogenate, which checked in 11% below projections.

Consumer health sales for the quarter also took a hit, thanks to China’s move to switch two skincare brands from OTC to prescription. The move precipitated a €70 million sales decline, Bernstein analyst Jeremy Redenius wrote in a note to clients.

Bayer’s 2018 outlook didn’t inspire a whole lot of confidence, either. As Redenius put it, it “looks to be soft vs. consensus,” with the company expecting €16.5 billion in pharma sales—more than $1 billion less than the €17.6 billion analysts expected. On the consumer side, Bayer expects €5.5 billion, short of Wall Street’s €6 billion guess. And as far as earnings go, the Leverkeusen-based company expects its bottom-line tally for both units to decline by a single-digit percentages before special items.

While Bayer’s consumer health segment has been struggling since 2014’s $14.2 billion fold-in of Merck’s OTC products, the pharma woes are newer. The company has touted big things ahead for the Eylea-Xarelto-Adempas-Stivarga-Xofigo group, even raising its guidance for the drugs in late 2016 to ease Monsanto-related fears.

But the third quarter didn’t exactly go as planned either—Redenius labeled those results “messy.” And with the Monsanto deal sapping funds that could have been used to develop Bayer’s pharma pipeline, that’s not a good sign.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).